von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects
about
Endothelial dysfunction in diabetes mellitus: possible involvement of endoplasmic reticulum stress?Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factorPrognostic implications of retinopathy and a high plasma von Willebrand factor concentration in type 2 diabetic subjects with microalbuminuria.Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.von Willebrand factor: two sides of a coin.Procoagulant factors and the risk of myocardial infarction in young women.The role of von Willebrand factor in hemorrhagic and thrombotic disorders.Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?Cardiovascular risk assessment in patients with diabetes.Diabetes is a proinflammatory state: a translational perspective.The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke.Obesity, haemostasis and the fibrinolytic system.Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study.The role of PCI and CABG in the management of coronary artery disease in patients with diabetes.Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes TrialShould we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 DiabetesVon Willebrand factor and thrombosis.von Willebrand factor, endothelial dysfunction, and cardiovascular disease.ADAMTS13: a new link between thrombosis and inflammation.The use of high-sensitivity assays for C-reactive protein in clinical practice.NALP3-Inflammasome-Related Gene Polymorphisms in Patients with Prehypertension and Coronary Atherosclerosis.Genetic predictors of depressive symptoms in cardiac patients.Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity.Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus.Should we measure C-reactive protein on earth or just on JUPITER?Assessment of endothelial dysfunction.Health effects of particulate air pollution: A review of epidemiological evidence.High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?von Willebrand factor: at the crossroads of bleeding and thrombosis.Is the risk and nature of CVD the same in type 1 and type 2 diabetes?Effect of vitamin B12 and folic acid supplementation on biomarkers of endothelial function and inflammation among elderly individuals with hyperhomocysteinemia.The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy.Positive association between high-sensitivity C-reactive protein and incidence of type 2 diabetes mellitus in Japanese workers: 6-year follow-up.Alcohol and red wine consumption, but not fruit, vegetables, fish or dairy products, are associated with less endothelial dysfunction and less low-grade inflammation: the Hoorn Study.Work-family life courses and markers of stress and inflammation in mid-life: evidence from the National Child Development Study.Intracoronary Imaging, Cholesterol Efflux, and Transcriptomics after Intensive Statin Treatment in Diabetes.A healthy diet is associated with less endothelial dysfunction and less low-grade inflammation over a 7-year period in adults at risk of cardiovascular disease.Glycemic control modifies the association between microalbuminuria and c-reactive protein in Type 2 Diabetes Mellitus.
P2860
Q26851362-9B174537-F0CC-4288-8333-B6E7EB3A31C9Q28261811-FCF4691D-4003-4774-90CF-B5FD81879D9CQ32135671-5852C63D-CCEE-4495-AA65-BB7BEF8BC7A1Q33283202-38F8E12B-E9A4-4664-BF6B-2321485949E0Q33367858-5E009C18-F414-4849-83FE-00E981AB66BCQ33370819-E9C9DD15-BC71-4AFB-B1CB-8F6730FD4BFDQ33374578-112FEAF6-2A6F-499E-888E-55AF761065A5Q33474334-06A4EC08-986B-48C4-9FED-2F721B5CF464Q33582582-ED90AD71-51D7-4C70-A4FF-F45CAB8DCF71Q33693974-842B0AB0-B61C-4E48-A57A-A6588AFDF52DQ34054032-A5579042-10EC-4BC1-979C-A5F5B0D8A7D2Q34743382-60940EF0-6F64-478D-B187-CC3249FA0B07Q34969475-58799483-CD40-4C05-B974-66EFF05123AEQ35087384-B98480A1-7549-4B68-B5F3-C484A0845564Q35757048-D12E1101-586F-4F04-95C4-194FD766C34DQ35788919-CE591A8C-BD4E-4EAD-95BC-63F087323614Q35932408-86195AFE-01B4-4DD5-A297-92184DB041FBQ36433738-41B7696F-41A0-43F0-AF1B-D045E91A8842Q36481209-08823E53-FFED-4E60-99B4-0DD749875FBFQ36853418-88E926FE-2AA8-4ABC-9448-224AE3E14EDBQ37090943-D4690E9D-7C23-4A8D-B7DC-CB21EBC3B430Q37092859-20C0B791-3BA1-4166-82AE-4F7BB0D3CB82Q37139308-3D4162A5-39AB-4A2C-97E8-26D6A8266CC2Q37157478-7B10EF8D-B7BC-4C98-AABF-0D0F40555948Q37305491-F4B6CE7B-DE62-40DD-A84E-E0F1A4900723Q37685079-25B500B3-0A95-46C8-94CB-C22AA36C2B8FQ37731432-6D39291C-9305-46A7-86C6-5CE9CAC54BF7Q37732250-748F9BBF-DEF4-4CA7-8E5A-89D8E428414FQ37921792-F03E14A0-A7F9-4EBB-80BD-9932537BA7EAQ37980496-61596D54-360D-4A47-BE0B-94698473C981Q38000162-C8D7E9C4-3656-45F8-92E1-331E1A420D22Q38092010-3848735B-8B55-41D5-B546-A926F36FB717Q38397154-95307EB2-3AED-44D5-8CD5-32DFCD040290Q38716432-A207F889-5EA7-458A-9E1D-B9D5F29E4DCCQ40095999-3D4394B0-B3FB-47AD-88F0-C2752EA55EE1Q40270866-A8A290FE-4479-4020-882C-876F65291525Q40431102-F6F15889-2E7B-4C5A-A65B-6A7DF2DCC6D3Q41203311-54087E68-A449-44E1-A1FA-43FC79C8DBA6Q41316492-DC0416EB-9DC3-442A-BC50-C22E259B2891Q41838292-C858CE03-61C3-41B8-9630-865932A332C0
P2860
von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects
description
article
@en
im Dezember 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1999
@uk
name
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@en
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@nl
type
label
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@en
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@nl
prefLabel
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@en
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@nl
P2093
P50
P1476
von Willebrand Factor, C-React ...... betic and Nondiabetic Subjects
@en
P2093
Agnes Jager
Jef J. Emeis
John S. Yudkin
Piet J. Kostense
Victor W. M. van Hinsbergh
P304
P356
10.1161/01.ATV.19.12.3071
P407
P577
1999-12-01T00:00:00Z